Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 756.69

-1.4%

3:49 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Miljenko Zuanic who wrote (83)	4/27/1997 10:47:00 PM
From: cl	of 3559

James and mz and others interested in regn... Amgen is going to hold its annual meeting on May 8 (10:30 am) at Regent Beverly Wilshire in L.A. I think we can think up of some good questions, huh? I might go... In Amgen's annual report, they cited the failure of BDNF as reminder of risks in clinical develoopment. Also, it continues to collaborate with regn in "investigating possible treatments for other diseases of the nervouse system with its product candidates BDNF and NT-3". At the mean time, NT-3 and bdnf are being tested in diabetic neuropathy, bdnf is used in intrathecal administration for ALS, gdnf in als, all in P2. Chuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next